| Jun 25 |
Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?
|
| Jun 19 |
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
|
| Jun 18 |
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
|
| Jun 17 |
Ionis to present at TD Cowen Genetic Medicines & RNA Summit
|
| Jun 15 |
ALS therapy market seen increasing to nearly $1.3B by 2029
|
| Jun 6 |
Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound?
|
| Jun 1 |
Shareholders Will Probably Not Have Any Issues With Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation
|
| May 31 |
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
|
| May 31 |
Ionis hereditary angioedema therapy succeeds in late-stage trials
|
| May 31 |
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
|
